NCT03227055

Cardiovascular Comorbidity in Children With Chronic Kidney Disease

Completed Last updated 20 February 2024

What this trial tests

trial in Childhood Chronic Kidney Disease in 155 participants. Completed in 31 December 2019.

Timeline

30 December 2016

Primary endpoint
31 December 2019

31 December 2019

Quick facts

Lead sponsor	Chang Gung Memorial Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	155
Start date	30 December 2016
Primary completion	31 December 2019
Estimated completion	31 December 2019
Sites	1 location across Taiwan

Conditions studied

• Childhood Chronic Kidney Disease — all drugs for Childhood Chronic Kidney Disease →

Sponsor

Chang Gung Memorial Hospital

Who can join

Adults 3 to 18, any sex, with Childhood Chronic Kidney Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This 3-year study will systematically evaluate the prevalence, clinical symptoms, and progression of CV and kidney disease and assess the impact of potential genetic, pharmacological, behavior, and environmental risk factors in a prospective cohort with a sample size of 125 aged 3-18 years children with stage G1-G4 chronic kidney disease (CKD). Measurements of morphological (e.g., LVMI \& cIMT) and functional characteristics (e.g., FMD \& PWV) of the cardiovascular system and 24hr ABPM profile will serve as surrogate end points for CV comorbidity in this study. Possible associations of these end points with multiple molecular (ADMA \& urine exosome miRNA), perceived value and behavior (EQ-5D-Y), pharmacological (NHIRD and CGRD), and environmental risk factors (patient and family survey) will be explored.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

1. Potential Use of Exosomes as Diagnostic Biomarkers and in Targeted Drug Delivery: Progress in Clinical and Preclinical Applications.
   Huda MN, Nafiujjaman M, Deaguero IG, Okonkwo J, et al · · 2021 · cited 160× · PMID 33988964 · DOI 10.1021/acsbiomaterials.1c00217
2. Let-7i-5p Regulation of Cell Morphology and Migration Through Distinct Signaling Pathways in Normal and Pathogenic Urethral Fibroblasts.
   Zhang K, Yang R, Chen J, Qi E, et al · · 2020 · cited 11× · PMID 32478052 · DOI 10.3389/fbioe.2020.00428
3. Basic Pathogenic Mechanisms and Epigenetic Players Promoted by Extracellular Vesicles in Vascular Damage.
   Schiano C, Balbi C, de Nigris F, Napoli C. · · 2023 · cited 7× · PMID 37108672 · DOI 10.3390/ijms24087509